Axogen, Inc. — Director's Dealing 2022

Jun 3, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Axogen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2022-06-01

Reporting Person: Gold Mark Stephen (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-01	Common Stock	M	3036	—	Acquired	305475	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-01	Restricted Stock Units	$	M	3036	Disposed		Common Stock (3036.0)	Direct
2022-06-01	Restricted Stock Units	$	A	6459	Acquired		Common Stock (6459.0)	Direct
2022-06-01	Stock Option (right to purchase)	$9.29	A	11811	Acquired	2032-06-01	Common Stock (11811.0)	Direct

Footnotes

F1: This reflects the number of restricted stock units that vested on June 1, 2022.

F2: The shares of common stock for Dr. Gold include 31,900 shares held directly, 159,575 shares held jointly by Dr. Gold and his wife, indirect ownership of 22,000 shares held by Dr. Gold's spouse in revocable trusts, and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust.

F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

F5: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.